Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vyvanse
Pharma
Takeda eyes upcoming launches as Vyvanse generics hit lingers
The company has three key phase 3 readouts this year, which it hopes will contribute to long-term growth despite a flat outlook for 2025.
Zoey Becker
May 8, 2025 10:36am
Astellas, AstraZeneca, Glenmark and more—Fierce Pharma Asia
Sep 6, 2024 9:00am
DEA raises production quota on Takeda's Vyvanse and its generics
Sep 4, 2024 3:24pm
Takeda's Entyvio keeps its strong IBD position despite threats
Jul 31, 2024 4:43pm
Teva's Adderall back in stock
May 22, 2024 5:44pm
Takeda plots $900M restructuring plan as profits plummet
May 9, 2024 12:00pm
